Read more at MarketWatch.
EyePoint Pharmaceuticals’ stock plunges as eye treatment fails to meet trial goal
Date: |
Sort by
Filter
Date
Items per page
-
Biogen and Ionis Pharma shares slide as they end development of ALS treatment
The move comes after early-stage trial failed to result in a clear signal it slowed the disease process.MarketWatch - Business -
FDA approves Amgen's treatment for most deadly form of lung cancer
The FDA cleared the Amgen drug, called Imdelltra, as a treatment for patients with advanced small-cell lung cancer.CNBC - Business - FDA -
Amgen gets FDA approval for small-cell lung-cancer treatment
Amgen on Thursday received approval from U.S. regulators for its drug to treat a form of late-stage lung-cancer.MarketWatch - Business - FDA -
Graduate workers in California to strike over treatment of Gaza protesters
Widespread disruption expected after workers vote to hold series of strikes, starting Monday with UC Santa Cruz. California’s huge university system is facing widespread disruption after workers voted to hold a series of strikes in protest of its ...The Guardian - World - California -
Under Armour is laying off workers as retailer says North America sales will plunge this year
Sales in Under Armour's largest market in North America are falling as inflation-weary consumers pull back on new clothes and shoes.CNBC - Business -
This Designer’s Goal Is Honoring the Stone
Ming Lampson focuses on finding and showcasing exceptional gems.The New York Times - Lifestyle -
Trump’s New York Trial: Where Page Six Meets ‘12 Angry Men’
The machinery of celebrity is being laid bare in a Manhattan courtroom amid the first criminal prosecution of a former U.S. president.The New York Times - Top stories - New York -
Eye on America: Protecting and preserving the environment
In California, we learn how the site of past environmental disasters could be a key to America’s clean energy future. Then in Florida, we explore restoration efforts to reverse years of devastation in the Everglades. Watch these stories and more ...CBS News - Top stories
More from MarketWatch
-
‘He’s holding all the cards’: My mother, 86, has dementia. Her partner of 30 years is on the deed to her home. How can I gain control of her finances?
“I asked to be put on the deed to my mother’s home and I was met with a swift ‘no’ from her partner. He said that since he had paid off the mortgage, the house is his.”MarketWatch - Business -
I got bitten by a feral cat and my hospital copay wiped out my savings. I’m 50, single, with no kids. Should I cash out my $12,000 life-insurance policy?
“I was thinking about cashing it out, and using the money to max out a SEP or Roth IRA for the year. Can I max out both? Or only one.”MarketWatch - Business -
Looking to place a wager on the Preakness? Here’s how to become a savvy bettor.
The second leg of racing’s Triple Crown is set for Saturday at 6:40 p.m. Eastern time.MarketWatch - Business -
‘I don’t want to end up with stalkers’: Should I tell my heirs that I’m writing a will and how much they can expect to inherit?
“Should I even let them know that there is a will in which they are mentioned?”MarketWatch - Business -
‘I racked up $45,000 in credit-card debt doing home repairs’: Should I refinance my $1.5 million house — or take out a personal loan to pay it off?
“We live in a very strong housing market in Los Angeles so we’re not worried about it losing value.”MarketWatch - Business